Concepts (131)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neoplasms | 7 | 2024 | 90 | 1.830 |
Why?
|
| Protein-Arginine N-Methyltransferases | 4 | 2024 | 8 | 1.820 |
Why?
|
| Tumor Microenvironment | 5 | 2021 | 27 | 1.090 |
Why?
|
| Melanoma | 6 | 2023 | 28 | 1.030 |
Why?
|
| Mice | 14 | 2024 | 685 | 1.010 |
Why?
|
| Purine-Nucleoside Phosphorylase | 1 | 2024 | 2 | 0.880 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2023 | 4 | 0.830 |
Why?
|
| Animals | 14 | 2024 | 1711 | 0.810 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2022 | 12 | 0.730 |
Why?
|
| CRISPR-Cas Systems | 2 | 2024 | 9 | 0.730 |
Why?
|
| Tumor Escape | 1 | 2021 | 4 | 0.680 |
Why?
|
| RNA, Long Noncoding | 1 | 2021 | 14 | 0.680 |
Why?
|
| Humans | 19 | 2024 | 4936 | 0.680 |
Why?
|
| Genomics | 1 | 2021 | 38 | 0.660 |
Why?
|
| Mice, Inbred C57BL | 4 | 2024 | 184 | 0.600 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 5 | 2024 | 9 | 0.600 |
Why?
|
| Immunotherapy | 7 | 2024 | 20 | 0.560 |
Why?
|
| Cell Line, Tumor | 6 | 2024 | 160 | 0.560 |
Why?
|
| T-Lymphocytes | 3 | 2024 | 46 | 0.530 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 2 | 2024 | 4 | 0.430 |
Why?
|
| Receptor-Interacting Protein Serine-Threonine Kinases | 2 | 2024 | 7 | 0.390 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2021 | 22 | 0.380 |
Why?
|
| Female | 6 | 2024 | 2523 | 0.260 |
Why?
|
| Arginine | 2 | 2023 | 6 | 0.240 |
Why?
|
| Immunity | 2 | 2023 | 8 | 0.240 |
Why?
|
| Cell Differentiation | 2 | 2023 | 71 | 0.230 |
Why?
|
| Ubiquitin-Activating Enzymes | 1 | 2024 | 2 | 0.220 |
Why?
|
| Pyroptosis | 1 | 2024 | 2 | 0.220 |
Why?
|
| RNA, Double-Stranded | 1 | 2024 | 2 | 0.220 |
Why?
|
| Repressor Proteins | 2 | 2023 | 13 | 0.220 |
Why?
|
| Taxoids | 1 | 2024 | 4 | 0.220 |
Why?
|
| Isoquinolines | 1 | 2024 | 5 | 0.220 |
Why?
|
| Pyrimidines | 1 | 2024 | 6 | 0.220 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2024 | 11 | 0.220 |
Why?
|
| Endoribonucleases | 1 | 2024 | 9 | 0.220 |
Why?
|
| Tauopathies | 1 | 2024 | 2 | 0.210 |
Why?
|
| tau Proteins | 1 | 2024 | 6 | 0.210 |
Why?
|
| Mice, Inbred MRL lpr | 1 | 2023 | 2 | 0.210 |
Why?
|
| Genome-Wide Association Study | 1 | 2024 | 12 | 0.210 |
Why?
|
| Gene Dosage | 1 | 2023 | 6 | 0.210 |
Why?
|
| Autoimmunity | 1 | 2023 | 5 | 0.210 |
Why?
|
| Antiviral Agents | 1 | 2024 | 16 | 0.210 |
Why?
|
| Mice, Transgenic | 2 | 2021 | 47 | 0.200 |
Why?
|
| Biomarkers, Tumor | 2 | 2021 | 15 | 0.200 |
Why?
|
| Neuroprotective Agents | 1 | 2023 | 13 | 0.200 |
Why?
|
| Cell Proliferation | 2 | 2021 | 115 | 0.200 |
Why?
|
| Positron-Emission Tomography | 2 | 2020 | 5 | 0.200 |
Why?
|
| Parkinson Disease | 1 | 2023 | 39 | 0.200 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2023 | 7 | 0.200 |
Why?
|
| Neoplasms, Second Primary | 1 | 2023 | 1 | 0.200 |
Why?
|
| Neurons | 1 | 2024 | 109 | 0.190 |
Why?
|
| Interleukin-2 | 1 | 2022 | 4 | 0.180 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2021 | 1 | 0.180 |
Why?
|
| Chromosome Deletion | 1 | 2021 | 3 | 0.180 |
Why?
|
| Glutaminase | 1 | 2020 | 2 | 0.170 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2021 | 19 | 0.170 |
Why?
|
| Aurora Kinase B | 1 | 2020 | 1 | 0.170 |
Why?
|
| Aurora Kinase A | 1 | 2020 | 2 | 0.170 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2020 | 8 | 0.170 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2020 | 1 | 0.160 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2020 | 9 | 0.160 |
Why?
|
| Oxidative Phosphorylation | 1 | 2019 | 1 | 0.150 |
Why?
|
| MAP Kinase Signaling System | 1 | 2019 | 6 | 0.150 |
Why?
|
| Receptors, CXCR5 | 1 | 2019 | 1 | 0.150 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2019 | 25 | 0.150 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2019 | 17 | 0.150 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2019 | 37 | 0.150 |
Why?
|
| B7-H1 Antigen | 3 | 2024 | 4 | 0.140 |
Why?
|
| Prognosis | 3 | 2021 | 60 | 0.120 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2024 | 29 | 0.100 |
Why?
|
| Disease Models, Animal | 2 | 2024 | 225 | 0.090 |
Why?
|
| Survival Rate | 2 | 2020 | 14 | 0.080 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2024 | 4 | 0.060 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2024 | 1 | 0.060 |
Why?
|
| Proteolysis | 1 | 2024 | 7 | 0.060 |
Why?
|
| DNA Damage | 1 | 2024 | 9 | 0.060 |
Why?
|
| Bridged-Ring Compounds | 1 | 2024 | 2 | 0.060 |
Why?
|
| Ovarian Neoplasms | 1 | 2024 | 13 | 0.050 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2024 | 12 | 0.050 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2024 | 40 | 0.050 |
Why?
|
| Antigens, CD | 1 | 2024 | 6 | 0.050 |
Why?
|
| Inflammasomes | 1 | 2024 | 40 | 0.050 |
Why?
|
| Receptor, Melanocortin, Type 1 | 1 | 2023 | 1 | 0.050 |
Why?
|
| DNA Replication | 1 | 2023 | 5 | 0.050 |
Why?
|
| Lipopolysaccharides | 1 | 2023 | 12 | 0.050 |
Why?
|
| Dopamine | 1 | 2023 | 26 | 0.050 |
Why?
|
| Dopaminergic Neurons | 1 | 2023 | 22 | 0.050 |
Why?
|
| Cell Line | 1 | 2023 | 84 | 0.050 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2023 | 7 | 0.050 |
Why?
|
| Proteomics | 1 | 2023 | 19 | 0.050 |
Why?
|
| DNA Copy Number Variations | 1 | 2023 | 8 | 0.050 |
Why?
|
| Alzheimer Disease | 1 | 2024 | 62 | 0.050 |
Why?
|
| RNA | 1 | 2023 | 29 | 0.050 |
Why?
|
| Overweight | 1 | 2023 | 40 | 0.050 |
Why?
|
| Body Mass Index | 1 | 2023 | 98 | 0.050 |
Why?
|
| Risk Factors | 1 | 2023 | 159 | 0.050 |
Why?
|
| Cytokines | 1 | 2022 | 37 | 0.040 |
Why?
|
| Immune Tolerance | 1 | 2021 | 1 | 0.040 |
Why?
|
| Homozygote | 1 | 2021 | 5 | 0.040 |
Why?
|
| Obesity | 1 | 2023 | 115 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2021 | 26 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 2020 | 9 | 0.040 |
Why?
|
| Apoptosis | 1 | 2020 | 46 | 0.040 |
Why?
|
| Radiopharmaceuticals | 1 | 2020 | 1 | 0.040 |
Why?
|
| Glycolysis | 1 | 2020 | 4 | 0.040 |
Why?
|
| Transcriptome | 1 | 2020 | 43 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 2020 | 25 | 0.040 |
Why?
|
| Oxadiazoles | 1 | 2019 | 1 | 0.040 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2019 | 3 | 0.040 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2019 | 3 | 0.040 |
Why?
|
| Signal Transduction | 1 | 2021 | 216 | 0.040 |
Why?
|
| Heterografts | 1 | 2019 | 8 | 0.040 |
Why?
|
| Piperidines | 1 | 2019 | 15 | 0.040 |
Why?
|
| Mitochondria | 1 | 2019 | 20 | 0.040 |
Why?
|
| Lymphoma, Follicular | 1 | 2019 | 1 | 0.040 |
Why?
|
| Germinal Center | 1 | 2019 | 1 | 0.040 |
Why?
|
| United States | 1 | 2022 | 495 | 0.040 |
Why?
|
| Palatine Tonsil | 1 | 2019 | 2 | 0.040 |
Why?
|
| Adoptive Transfer | 1 | 2019 | 4 | 0.040 |
Why?
|
| Coculture Techniques | 1 | 2019 | 9 | 0.040 |
Why?
|
| Protein Kinases | 1 | 2019 | 17 | 0.040 |
Why?
|
| B-Lymphocytes | 1 | 2019 | 7 | 0.040 |
Why?
|
| Lymphocyte Activation | 1 | 2019 | 15 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2019 | 12 | 0.040 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2019 | 8 | 0.040 |
Why?
|
| Transcription, Genetic | 1 | 2019 | 17 | 0.040 |
Why?
|
| Transforming Growth Factor beta | 1 | 2019 | 10 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2019 | 55 | 0.040 |
Why?
|
| Mice, Knockout | 1 | 2019 | 140 | 0.040 |
Why?
|
| Retrospective Studies | 1 | 2020 | 341 | 0.040 |
Why?
|
| Male | 1 | 2019 | 2491 | 0.020 |
Why?
|